The in-licensing of a late-stage, already-approved-in-China asset (ciprocopan) combined with a well-capitalized balance sheet ($115M raised) represents a major de-risking event. Traders should watch for the upcoming pre-IND meeting with the FDA in 4Q2026 and the ESMO presentation for NXP200 in October 2026 as the next catalysts.
Price Chart
Executive Summary
Nuvectis Pharma reported Q2 2026 results highlighting a transformative in-licensing of ciprocopan (NXP100) and NXP200 from Haisco, with ciprocopan receiving its first marketing approval in China for PNH. The company completed a $115M follow-on offering in July, extending its cash runway into 1H 2029. Net loss widened to $7.0M from $6.3M YoY, but the pipeline transformation and strong cash position are the key drivers for the stock.
Key Financial Metrics
Key Facts
- In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco, transforming the company into a late-stage clinical organization.
- Ciprocopan received first marketing approval in China for PNH in July 2026; US IND submission expected in 4Q2026.
- Completed a follow-on offering in July 2026, raising $115M in gross proceeds, extending cash runway into 1H 2029.
- Q2 2026 net loss was $7.0M vs $6.3M YoY; cash and equivalents were $22.2M as of June 30, 2026, before the $115M raise.
Financial Impact
$115M gross proceeds from July follow-on offering; net loss increased $0.7M YoY to $7.0M
Risk Factors
- Ciprocopan's US regulatory path is unproven; a pre-IND meeting and IND submission are still pending.
- Dilution from the $115M follow-on offering will pressure share count.
- NXP900 clinical development is being deprioritized, reducing near-term oncology pipeline optionality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-090094 |
| Document: tm2622125d1_8k.htm | 0001104659-26-090094 |
| Document: 0001104659-26-090094-index-headers.html | 0001104659-26-090094 |
| Document: 0001104659-26-090094-index.html | 0001104659-26-090094 |
| Document: 0001104659-26-090094.txt | 0001104659-26-090094 |
| 8-K Data (Synthetic) | 0001104659-26-090094 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 11w ago | 8-K | $20.10 $23.06 | ▲ +14.73% | ▲ +15.96% | $18.49 (−8.01%) |
Jul 1, 2026 16w ago | Insider Cluster | $19.52 $20.69 | ▲ +5.99% | ▲ +8.18% | $18.49 (−5.28%) |
Jun 30, 2026 16w ago | 8-K | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 30, 2026 16w ago | 424B5 | $19.52 $20.69 | ▼ −5.99% | ▼ −8.18% | $18.49 (+5.28%) |
Jun 29, 2026 17w ago | Press Release | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 424B5 | $18.39 $19.54 | ▼ −6.25% | ▼ −7.28% | $18.49 (−0.54%) |
Jun 29, 2026 17w ago | 8-K | $18.39 $19.54 | ▲ +6.25% | ▲ +7.28% | $18.49 (+0.54%) |
May 5, 2026 24w ago | 8-K | $9.71 $9.51 | ▼ −2.06% | ▼ −7.01% | $18.49 (+90.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers